ADMA Biologics, Inc. Q3 2025 Earnings Recap

ADMA Q3 2025 November 6, 2025

Get alerts when ADMA reports next quarter

ADMA Biologics reported a strong third quarter of 2025, with total revenue reaching $134.2 million, showcasing solid sequential and year-over-year growth driven by record utilization of ASCENIV and operational advancements.

Earnings Per Share Beat

$0.16 vs $0.16 est.

+0.0% surprise

Revenue Miss

134224000 vs 139800000 est.

-4.0% surprise

Market Reaction

1-Day -8.72%

5-Day +4.29%

30-Day +26.09%

See ADMA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenue increased 10% quarter-over-quarter and 12% year-over-year to $134.2 million.
GAAP net income rose to $36.4 million, a 6% increase from the previous quarter and 1% year-over-year.
Adjusted EBITDA grew by 16% quarter-over-quarter and 29% year-over-year to $58.7 million, indicating enhanced operational leverage.
ASCENIV observed significant patient-driven demand, with promising payer negotiations expected to improve reimbursement access in 2026.
Operational advancements, including FDA regulatory approval for yield-enhanced production, are projected to enhance gross margins substantially starting Q4 2025.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ADMA on AllInvestView.

Next Q1 2026